PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer
-
Published:2020-08
Issue:
Volume:152
Page:102973
-
ISSN:1040-8428
-
Container-title:Critical Reviews in Oncology/Hematology
-
language:en
-
Short-container-title:Critical Reviews in Oncology/Hematology
Author:
Post Cathalijne C.B.ORCID,
Westermann Anneke M.,
Bosse Tjalling,
Creutzberg Carien L.ORCID,
Kroep Judith R.
Subject
Oncology,Hematology
Reference73 articles.
1. Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression;Ashley;Gynecol. Oncol.,2019
2. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer;Bosse;Mod. Pathol.,2013
3. Combining PARP inhibition, radiation, and immunotherapy: A possible strategy to improve the treatment of cancer?;Cesaire;Int. J. Mol. Sci.,2018
4. Pembrolizumab treatment of advanced cervical cancer: updated results from the phase 2 KEYNOTE-158 study;Chung;J. Clin. Oncol.,2018
5. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial;Coleman;Lancet.,2017
Cited by
35 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献